|Bid||31.00 x 1100|
|Ask||49.44 x 1100|
|Day's Range||30.68 - 31.74|
|52 Week Range||28.88 - 54.98|
|Beta (5Y Monthly)||1.21|
|PE Ratio (TTM)||2.65|
|Earnings Date||Oct 27, 2022 - Oct 31, 2022|
|Forward Dividend & Yield||0.60 (1.79%)|
|Ex-Dividend Date||Aug 11, 2022|
|1y Target Est||N/A|
Oppenheimer & Co. Inc. ("Oppenheimer") – a leading wealth manager, investment bank, and a subsidiary of Oppenheimer Holdings (NYSE: OPY) –announced that its second annual ESG Summit, Navigating the ESG & Climate Transition, starts today.
Top-Rated Invesco Oppenheimer Funds as of 8/31/22 Fund Name, Ticker, Overall Rating, (Risk Grade) Invesco Balanced Risk Com Str A A+ (B-) Invesco Premier Portfolio Inst IPPXX A+ (A+) Invesco US Managed ...
Oppenheimer & Co. Inc. ("Oppenheimer") – a leading investment bank, wealth manager, and a subsidiary of Oppenheimer Holdings (NYSE: OPY) – today announced the ongoing expansion of its Healthcare Life Sciences Research Team within the firm's Equity Research Department with the appointment of Joel Sendek as Managing Director and Head of Healthcare Life Sciences Equity Research. Mr. Sendek will report to John Parks, Managing Director and Director of Equity Research at Oppenheimer.